Colorectal CancerFDA Approvals, News & UpdatesNewsworthy

Opdivo Approved for dMMR and MSI-H Metastatic Colorectal Cancer

December 2017 Vol 3 No 6

On July 31, 2017, the FDA approved a new use for Opdivo (nivolumab; from Bristol-Myers Squibb) for adults with mismatch repair–deficient (dMMR) and microsatellite instability–high (MSI-H) metastatic colorectal cancer that progressed after treatment with a chemotherapy regimen.

The approval of this new indication was based on a clinical trial showing that 28% of adult patients responded to treatment with Opdivo, including 1 complete response (no sign of disease) and 14 partial responses. In 67% of patients, the responses lasted 6 months or longer. Among the 74 patients in the overall population, there was an objective response rate of 32%.

Opdivo was previously approved by the FDA for many types of cancer, including melanoma, lung cancer, kidney cancer, head and neck cancer, liver cancer, lymphoma, and bladder cancer.

Recommended For You
Breast CancerFDA Approvals, News & Updates
Trodelvy New Therapy Approved for Triple-Negative Breast Cancer
In April, 2020, the FDA approved Trodelvy for the treatment of adults with metastatic triple-negative breast cancer after 2 or more previous therapies.
BiomarkersFDA Approvals, News & Updates
Tabrecta Approved for NSCLC with MET Biomarker

On May 6, 2020, the FDA approved Tabrecta (capmatinib; from Novartis), an oral kinase inhibitor, for adults with metastatic (spreading) non–small-cell lung cancer (NSCLC).

FDA Approvals, News & UpdatesOvarian Cancer
Zejula Now Approved as First-Line Maintenance Therapy in All Patients with Ovarian Cancer

On April 29, 2020, the FDA approved Zejula (niraparib; from GlaxoSmithKline), an oral PARP inhibitor, as the first PARP inhibitor approved for first-line maintenance (long-term) therapy for all patients with advanced ovarian cancer (including epithelial ovarian, fallopian tube, or primary peritoneal cancer) whose cancer had a complete or partial response to platinum-based chemotherapy.

CholangiocarcinomaFDA Approvals, News & Updates
Pemazyre First Therapy Approved for Cholangiocarcinoma with FGFR2 Biomarker
In April, the FDA approved Pemazyre, the first targeted drug for patients with advanced cholangiocarcinoma and a biomarker called FGFR2 gene fusion.
Last modified: January 2, 2018

Subscribe to CONQUER: the patient voice magazine

Receive timely cancer news & updates, patient stories, and more.